JP6901569B2 - 抗うつ化合物およびその製造方法と使用 - Google Patents

抗うつ化合物およびその製造方法と使用 Download PDF

Info

Publication number
JP6901569B2
JP6901569B2 JP2019536014A JP2019536014A JP6901569B2 JP 6901569 B2 JP6901569 B2 JP 6901569B2 JP 2019536014 A JP2019536014 A JP 2019536014A JP 2019536014 A JP2019536014 A JP 2019536014A JP 6901569 B2 JP6901569 B2 JP 6901569B2
Authority
JP
Japan
Prior art keywords
group
substituted
groups
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019536014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503341A (ja
JP2020503341A5 (https=
Inventor
チャンカン フアン
チャンカン フアン
ヤン リ
ヤン リ
フアリャン ジアン
フアリャン ジアン
ヤン シエ
ヤン シエ
フェイ グオ
フェイ グオ
ジューション リ
ジューション リ
ミンツァン チェン
ミンツァン チェン
ミンユエ チェン
ミンユエ チェン
チャオリン スン
チャオリン スン
ユー ガオ
ユー ガオ
シャオティン ティエン
シャオティン ティエン
ペイ フー
ペイ フー
ビン チャン
ビン チャン
Original Assignee
シャンハイ インスティチュート オブ マテリア メディカ，チャイニーズ アカデミー オブ サイエンシーズ
シャンハイ インスティチュート オブ マテリア メディカ，チャイニーズ アカデミー オブ サイエンシーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ インスティチュート オブ マテリア メディカ，チャイニーズ アカデミー オブ サイエンシーズ, シャンハイ インスティチュート オブ マテリア メディカ，チャイニーズ アカデミー オブ サイエンシーズ filed Critical シャンハイ インスティチュート オブ マテリア メディカ，チャイニーズ アカデミー オブ サイエンシーズ
Publication of JP2020503341A publication Critical patent/JP2020503341A/ja
Publication of JP2020503341A5 publication Critical patent/JP2020503341A5/ja
Application granted granted Critical
Publication of JP6901569B2 publication Critical patent/JP6901569B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019536014A 2016-12-30 2017-12-29 抗うつ化合物およびその製造方法と使用 Active JP6901569B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611260514.6 2016-12-30
CN201611260514.6A CN108264535A (zh) 2016-12-30 2016-12-30 一种抗抑郁化合物及其制备方法和应用
PCT/CN2017/120134 WO2018121770A1 (zh) 2016-12-30 2017-12-29 一种抗抑郁化合物及其制备方法和应用

Publications (3)

Publication Number Publication Date
JP2020503341A JP2020503341A (ja) 2020-01-30
JP2020503341A5 JP2020503341A5 (https=) 2021-05-27
JP6901569B2 true JP6901569B2 (ja) 2021-07-14

Family

ID=62707894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019536014A Active JP6901569B2 (ja) 2016-12-30 2017-12-29 抗うつ化合物およびその製造方法と使用

Country Status (5)

Country Link
US (1) US11142543B2 (https=)
EP (1) EP3564253B1 (https=)
JP (1) JP6901569B2 (https=)
CN (2) CN108264535A (https=)
WO (1) WO2018121770A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019129176A1 (zh) * 2017-12-29 2019-07-04 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
CN109988218B (zh) * 2017-12-29 2022-11-25 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
CN109206472A (zh) * 2018-09-27 2019-01-15 华东理工大学 薯蓣皂苷元衍生物、其药物组合物及其应用
CN109053854B (zh) * 2018-09-29 2021-05-14 深圳清博汇能医药科技有限公司 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用
WO2020259612A1 (zh) * 2019-06-26 2020-12-30 中国科学院上海药物研究所 一种抗抑郁甾体化合物
CN113831381A (zh) * 2020-06-24 2021-12-24 中国科学院上海药物研究所 一种用于治疗抑郁症的甾体化合物
CN113831382A (zh) * 2020-06-24 2021-12-24 中国科学院上海药物研究所 一种甾体化合物
CN113292629B (zh) * 2021-06-21 2022-04-26 西南民族大学 薯蓣皂苷元羟肟酸类衍生物及其制备方法和应用
EP4477225A4 (en) * 2022-02-18 2026-01-21 Beijing Phytovent Pharmaceutical Tech Co Ltd USE OF A SARSASAPOGENIN STRUCTURE-BASED DERIVATIVE AND ASSOCIATED PHARMACEUTICAL COMPOSITION
CN116621912A (zh) * 2022-02-18 2023-08-22 北京清博汇能医药科技有限公司 基于菝契皂苷元结构的衍生物及其药物组合物的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
PL213697B1 (pl) * 2002-03-27 2013-04-30 Phytopharm Plc Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych
WO2005051381A1 (en) * 2003-11-26 2005-06-09 Biovitrum Ab Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R)
WO2005051380A1 (en) * 2003-11-26 2005-06-09 Biovitrum Ab Substituted urea-octahydroindols as antagonists of melanin concentrating hormone receptor 1 (mch1r)
US20050245495A1 (en) * 2004-04-07 2005-11-03 Chen Zhao Azacyclosteroid histamine-3 receptor ligands
TW200621244A (en) 2004-08-19 2006-07-01 Vertex Pharma Modulators of muscarinic receptors
CN101214253B (zh) 2008-01-07 2011-09-21 中国人民解放军第二军医大学 知母皂苷b-ⅱ用于制备抗抑郁产品的用途
EP2262789A1 (en) 2008-03-05 2010-12-22 F. Hoffmann-La Roche AG 2-aminoquinolines
CN101768202B (zh) * 2009-02-18 2013-10-30 沈阳药科大学 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途
CN102924559B (zh) * 2012-11-16 2015-10-28 沈阳药科大学 菝葜皂苷元衍生物及其制备和应用
US20170129915A1 (en) 2014-04-25 2017-05-11 Resilio Company Limited Therapeutic agent for diseases associated with nerve axon dysfunction, including therapeutic agent for alzheimer's disease
WO2019129176A1 (zh) * 2017-12-29 2019-07-04 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用

Also Published As

Publication number Publication date
US11142543B2 (en) 2021-10-12
CN108264535A (zh) 2018-07-10
JP2020503341A (ja) 2020-01-30
EP3564253A1 (en) 2019-11-06
EP3564253B1 (en) 2024-10-30
WO2018121770A1 (zh) 2018-07-05
EP3564253A4 (en) 2020-07-29
CN110121502A (zh) 2019-08-13
US20200385418A1 (en) 2020-12-10
CN110121502B (zh) 2022-09-23

Similar Documents

Publication Publication Date Title
JP6901569B2 (ja) 抗うつ化合物およびその製造方法と使用
US20190083420A1 (en) Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
TWI579277B (zh) 取代桂皮醯胺衍生物、其製備方法、其應用及醫藥組成物
EP3617195B1 (en) Novel tetrahydronaphthyl urea derivatives as inhibitors of tropomyosin receptor kinase a for the treatment of pain
CN118948849A (zh) 用于预防和治疗与抗肥胖作用有关的疾病的药物
AU2017206382A1 (en) Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications
ES2881267T3 (es) Antagonistas/agonistas parciales selectivos del receptor D3 de dopamina; método de preparación; y uso de los mismos
CN109988218B (zh) 一种菝葜皂苷元衍生物及其制备方法和应用
TW202340145A (zh) 氘化有機化合物及其用途
WO2019129176A1 (zh) 一种菝葜皂苷元衍生物及其制备方法和应用
CN103360342A (zh) 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用
JP5486008B2 (ja) １‐ブチル‐２‐ヒドロキシアラルキルピペラジン誘導体およびその抗鬱剤としての使用
CN100415728C (zh) 烷醇哌嗪衍生物光学异构体或其盐及其制备药物的应用
CN107540636A (zh) 一种含氮杂环衍生物及其应用
WO2014159501A2 (en) Processes for preparing tetrahydroisoquinolines
WO2022125614A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
CN116217567B (zh) 烃基取代的α-咔啉类似物或其药用盐、其药物组合物及其制备方法和用途
EP0460358B1 (en) Agent for treating disorders from cerebral neuro-degeneration
CN112142817B (zh) 一种抗抑郁甾体化合物
CN115785094B (zh) 苄基取代α-咔啉化合物或其药用盐、其药物组合物及其制备方法和用途
WO2025223436A1 (en) Ptpn2/ptp1b degrader and synthesis methods thereof
ES2672326T3 (es) Analogos de tiazolidinona deuterados como agonistas para el receptor de la hormona folículo estimulante
US12540121B2 (en) Compositions comprising a retinoid X receptor (RXR) agonist, a retinoic acid receptor (RAR) agonist, or a dual RXR/RAR agonist
JPH01233284A (ja) 新規縮合ジアゼピノン類、その製法及びこれらの化合物を含む医薬組成物
HK40106138A (zh) 作为血清素能药物的用於治疗与之相关的疾病的吲哚衍生物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210112

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210412

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210518

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210617

R150 Certificate of patent or registration of utility model

Ref document number: 6901569

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250